Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose Targeted next-generation sequencing (NGS) is widely used for simultaneously detecting clinically informative genetic alterations in a single assay. Its application in clinical settings requires the validation of NGS gene panels. In this study, we aimed to validate a targeted hybridization capture-based DNA panel (ONCOaccuPanel) using the Illumina MiSeq sequencing platform. The panel allows the simultaneous detection of single-nucleotide variants (SNVs), insertions, deletions, and copy number changes of 323 genes and fusions of 17 genes in solid tumors. Materials and Methods We used 16 formalin-fixed paraffin-embedded (FFPE) tumor samples with previously known genetic mutations and one reference material (HD827) for validation. Moreover, we sequenced an additional 117 FFPE tumor samples to demonstrate the clinical utility of this panel. Results Validation revealed a 100% positive percentage agreement and positive predictive value for the detection of SNVs, insertions, deletions, copy number changes, fusion genes, and microsatellite instability–high types. We observed high levels of reproducibility and repeatability (R2 correlation coefficients=0.96-0.98). In the limit of detection assessment, we identified all clinically relevant genes with allele frequencies > 3%. Furthermore, the clinical application of ONCOaccuPanel using 117 FFPE samples demonstrated robust detection of oncogenic alterations. Oncogenic alterations and targetable genetic alterations were detected in 98.2% and 27.4% cases, respectively. Conclusion ONCOaccuPanel demonstrated high analytical sensitivity, reproducibility, and repeatability and is feasible for the detection of clinically relevant mutations in clinical settings.
Abstract
Purpose Targeted next-generation sequencing (NGS) is widely used for simultaneously detecting clinically informative genetic alterations in a single assay. Its application in clinical settings requires the validation of NGS gene panels. In this study, we aimed to validate a targeted hybridization capture-based DNA panel (ONCOaccuPanel) using the Illumina MiSeq sequencing platform. The panel allows the simultaneous detection of single-nucleotide variants (SNVs), insertions, deletions, and copy number changes of 323 genes and fusions of 17 genes in solid tumors. Materials and Methods We used 16 formalin-fixed paraffin-embedded (FFPE) tumor samples with previously known genetic mutations and one reference material (HD827) for validation. Moreover, we sequenced an additional 117 FFPE tumor samples to demonstrate the clinical utility of this panel. Results Validation revealed a 100% positive percentage agreement and positive predictive value for the detection of SNVs, insertions, deletions, copy number changes, fusion genes, and microsatellite instability–high types. We observed high levels of reproducibility and repeatability (R2 correlation coefficients=0.96-0.98). In the limit of detection assessment, we identified all clinically relevant genes with allele frequencies > 3%. Furthermore, the clinical application of ONCOaccuPanel using 117 FFPE samples demonstrated robust detection of oncogenic alterations. Oncogenic alterations and targetable genetic alterations were detected in 98.2% and 27.4% cases, respectively. Conclusion ONCOaccuPanel demonstrated high analytical sensitivity, reproducibility, and repeatability and is feasible for the detection of clinically relevant mutations in clinical settings.
참고문헌 (37)
- Chakravarty D, "Clinical cancer genomic profiling", Nat Rev Genet, 22, pp.483~501 (2021)
- Yatabe Y, "Multiplex gene-panel testing for lung cancer patients", Pathol Int, 70, pp.921~931 (2020)
- Pennell NA, "Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non-small-cell lung cancer using a decision analytic model", JCO Precis Oncol, 3, pp.1~9 (2019)
- Heist RS, "MET exon 14 skipping in non-small cell lung cancer", Oncologist, 21, pp.481~486 (2016)
- Kohno T, "Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer", Transl Lung Cancer Res, 4, pp.156~164 (2015)
- Vaishnavi A, "Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer", Nat Med, 19, pp.1469~1472 (2013)
- Skoulidis F, "Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy", Nat Rev Cancer, 19, pp.495~509 (2019)
- Polyak K, "Heterogeneity in breast cancer", J Clin Invest, 121, pp.3786~3788 (2011)
- Goodwin S, "Coming of age : ten years of next-generation sequencing technologies", Nat Rev Genet, 17, pp.333~351 (2016)
- Jennings LJ, "Guidelines for validation of next-generation sequencing-based oncology panels : a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists", J Mol Diagn, 19, pp.341~365 (2017)
- Aziz N, "College of American Pathologists’ laboratory standards for next-generation sequencing clinical tests", Arch Pathol Lab Med, 139, pp.481~493 (2015)
- Rehm HL, "ACMG clinical laboratory standards for next-generation sequencing", Genet Med, 15, pp.733~747 (2013)
- Gargis AS, "Assuring the quality of next-generation seq-uencing in clinical laboratory practice", Nat Biotechnol, 30, pp.1033~1036 (2012)
- 김지훈, "Good Laboratory Standards for Clinical Next-Generation Sequencing Cancer Panel Tests", Journal of Pathology and Translational Medicine, 51(3), pp.191~204 (2017), 대한병리학회[DOI]
- Roy S, "Standards and guidelines for validating next-generation sequencing bioinformatics pipelines : a joint recommendation of the Association for Molecular Pathology and the College of American Pathologists", J Mol Diagn, 20, pp.4~27 (2018)
- Kim JE, "Mutation burden and I index for detection of microsatellite instability in colorectal cancer by targeted next-generation sequencing", J Mol Diagn, 21, pp.241~250 (2019)
- Umar A, "Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer(Lynch syndrome)and microsatellite instability", J Natl Cancer Inst, 96, pp.261~268 (2004)
- Luchini C, "ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1", PD-L1 expression and tumour mutational burden : a systematic review-based approach, 2019, pp.30, 1232~1243
- Li MM, "Standards and guidelines for the interpretation and reporting of sequence variants in cancer : a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists", J Mol Diagn, 19, pp.4~23 (2017)
- Nakamura Y, "Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers : an emerging paradigm", Nat Rev Clin Oncol, 18, pp.473~487 (2021)
- Denny JC, "Precision medicine in 2030-seven ways to transform healthcare", Cell, 184, pp.1415~1419 (2021)
- Meyerson M, "Advances in understanding cancer genomes through second-generation sequencing", Nat Rev Genet, 11, pp.685~696 (2010)
- Cheng DT, "Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets(MSK-IMPACT) : a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology", J Mol Diagn, 17, pp.251~264 (2015)
- Bolivar AM, "Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA : identification of plasma-based, tumor-associated mutations in early stage patients", Mod Pathol, 32, pp.405~414 (2019)
- Cancer Genome Atlas Research Network, "Integrated genomic and molecular characterization of cervical cancer", Nature, 543, pp.378~384 (2017)
- Vang R, "Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma : a rereview of cases lacking TP53 mutations in the Cancer Genome Atlas Ovarian Study", Int J Gynecol Pathol, 35, pp.48~55 (2016)
- Ross JS, "Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies", Gynecol Oncol, 130, pp.554~559 (2013)
- Wei S, "Case report : short-term response to first-line crizotinib monotherapy in a metastatic lung adenocarcinoma patient harboring a novel TPR-ROS1 fusion", Front Oncol, 12, pp.862008~ (2022)
- Kao YC, "Soft tissue tumors characterized by a wide spectrum of kinase fusions share a lipofibromatosis-like neural tumor pattern", Genes Chromosomes Cancer, 59, pp.575~583 (2020)
- Pascual J, "Targeting the PI3-kinase pathway in triple-negative breast cancer", Ann Oncol, 30, pp.1051~1060 (2019)
- Hastings PJ, "Mechanisms of change in gene copy number", Nat Rev Genet, 10, pp.551~564 (2009)
- Pilie PG, "State-of-the-art strategies for targeting the DNA damage response in cancer", Nat Rev Clin Oncol, 16, pp.81~104 (2019)
- Li K, "Microsatellite instability : a review of what the oncologist should know", Cancer Cell Int, 20, pp.16~ (2020)
- Hampel H, "Screening for Lynch syndrome(hereditary nonpolyposis colorectal cancer)among endometrial cancer patients", Cancer Res, 66, pp.7810~7817 (2006)
- Ferguson SE, "Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing", Cancer, 120, pp.3932~3939 (2014)
- Klempner SJ, "Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors : a review of current evidence", Oncologist, 25, pp.e147~59 (2020)
- 이승은, "Interlaboratory Comparison Study (Ring Test) of Next-Generation Sequencing–Based NTRK Fusion Detection in South Korea", Cancer Research and Treatment, 55(1), pp.28~40 (2023), 대한암학회[DOI]